Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Merck & Co. discloses DGAT-2 inhibitors

March 17, 2016

Orexigen announces strategic acquisition of all rights to Contrave in the U.S.

March 16, 2016

Novel dual-target compounds inhibit inducible nitric oxide synthase and cannabinoid CB1 receptors

March 16, 2016

Shionogi presents AMPK activators

March 16, 2016

Adocia and Lilly present positive topline results from phase Ib study of BioChaperone Lispro

March 16, 2016

Ozgene knock-in mouse model to help advance diabetes research at University of Auckland

March 14, 2016

Sunnylife Pharma presents 5-HT2C receptor agonists

March 14, 2016

Scripps Florida receives funding for obesity and weight control research

March 10, 2016

Alnylam begins phase I/II trial of ALN-GO1 for primary hyperoxaluria type 1

March 10, 2016

CJ CheilJedang reports FFAR1 agonists for diabetes

March 10, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...